KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v266-v266 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v266 |
|---|---|
| container_issue | |
| container_start_page | v266 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Finn, R.S. Chan, S.L. Zhu, A.X. Knox, J. Cheng, A-L. Siegel, A.B. Bautista, O. Kudo, M. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx369.157 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx369_157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420380479</els_id><sourcerecordid>S0923753420380479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-8bec4c05d2d62b35e1ec696e84f5bc54d289f58995f8871843d87f5ad6168cb03</originalsourceid><addsrcrecordid>eNp9kLFOwzAURS0EEqXwAWweW4m0dhInNkwQFYqoKBJlYIoc-0U1SuLITivaD-F7aRVmpqc7nKv7DkLXlEwoEdFUNo1t1LTW31EiJpSlJ2hAWSICTmJ6igZEhFGQsig-RxfefxFCEhGKAfp5mX2-LlezIIzJLX5bSw84usFONtrWZg8a-26jd9iWuIW6cLYy-00tCzzq4xhvPS7Ad9hv2ta6zmwBK-kAjx7eszEurcMelG10UJkGsNRb2ahD7Rpa2VkFVbWppDsiyjS2lng0z7LxJTorZeXh6u8O0cfjbJXNg8Xy6Tm7XwSKcpYGvAAVK8J0qJOwiBhQUIlIgMclKxSLdchFybgQrOQ8pTyONE9LJnVCE64KEg0R7XuVs947KPPWmVq6XU5JfhSb92LzXmx-EHtg7noGDsO2BlzulYHjU8aB6nJtzT_0L0BIg6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Finn, R.S. ; Chan, S.L. ; Zhu, A.X. ; Knox, J. ; Cheng, A-L. ; Siegel, A.B. ; Bautista, O. ; Kudo, M.</creator><creatorcontrib>Finn, R.S. ; Chan, S.L. ; Zhu, A.X. ; Knox, J. ; Cheng, A-L. ; Siegel, A.B. ; Bautista, O. ; Kudo, M.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx369.157</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v266-v266</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1857-8bec4c05d2d62b35e1ec696e84f5bc54d289f58995f8871843d87f5ad6168cb03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids></links><search><creatorcontrib>Finn, R.S.</creatorcontrib><creatorcontrib>Chan, S.L.</creatorcontrib><creatorcontrib>Zhu, A.X.</creatorcontrib><creatorcontrib>Knox, J.</creatorcontrib><creatorcontrib>Cheng, A-L.</creatorcontrib><creatorcontrib>Siegel, A.B.</creatorcontrib><creatorcontrib>Bautista, O.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><title>KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kLFOwzAURS0EEqXwAWweW4m0dhInNkwQFYqoKBJlYIoc-0U1SuLITivaD-F7aRVmpqc7nKv7DkLXlEwoEdFUNo1t1LTW31EiJpSlJ2hAWSICTmJ6igZEhFGQsig-RxfefxFCEhGKAfp5mX2-LlezIIzJLX5bSw84usFONtrWZg8a-26jd9iWuIW6cLYy-00tCzzq4xhvPS7Ad9hv2ta6zmwBK-kAjx7eszEurcMelG10UJkGsNRb2ahD7Rpa2VkFVbWppDsiyjS2lng0z7LxJTorZeXh6u8O0cfjbJXNg8Xy6Tm7XwSKcpYGvAAVK8J0qJOwiBhQUIlIgMclKxSLdchFybgQrOQ8pTyONE9LJnVCE64KEg0R7XuVs947KPPWmVq6XU5JfhSb92LzXmx-EHtg7noGDsO2BlzulYHjU8aB6nJtzT_0L0BIg6Q</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Finn, R.S.</creator><creator>Chan, S.L.</creator><creator>Zhu, A.X.</creator><creator>Knox, J.</creator><creator>Cheng, A-L.</creator><creator>Siegel, A.B.</creator><creator>Bautista, O.</creator><creator>Kudo, M.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)</title><author>Finn, R.S. ; Chan, S.L. ; Zhu, A.X. ; Knox, J. ; Cheng, A-L. ; Siegel, A.B. ; Bautista, O. ; Kudo, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-8bec4c05d2d62b35e1ec696e84f5bc54d289f58995f8871843d87f5ad6168cb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Finn, R.S.</creatorcontrib><creatorcontrib>Chan, S.L.</creatorcontrib><creatorcontrib>Zhu, A.X.</creatorcontrib><creatorcontrib>Knox, J.</creatorcontrib><creatorcontrib>Cheng, A-L.</creatorcontrib><creatorcontrib>Siegel, A.B.</creatorcontrib><creatorcontrib>Bautista, O.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Finn, R.S.</au><au>Chan, S.L.</au><au>Zhu, A.X.</au><au>Knox, J.</au><au>Cheng, A-L.</au><au>Siegel, A.B.</au><au>Bautista, O.</au><au>Kudo, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v266</spage><epage>v266</epage><pages>v266-v266</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx369.157</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v266-v266 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx369_157 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T01%3A10%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KEYNOTE-240:%20Phase%203,%20randomized%20study%20of%20pembrolizumab%20(pembro)%20vs%20best%20supportive%20care%20(BSC)%20for%20second-line%20advanced%20hepatocellular%20carcinoma%20(HCC)&rft.jtitle=Annals%20of%20oncology&rft.au=Finn,%20R.S.&rft.date=2017-09&rft.volume=28&rft.spage=v266&rft.epage=v266&rft.pages=v266-v266&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx369.157&rft_dat=%3Celsevier_cross%3ES0923753420380479%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420380479&rfr_iscdi=true |